Gain insights from our experts...
Optimizing lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
The success of mRNA vaccines during the COVID-19 pandemic has accelerated the advancement of nucleic acid delivery technologies. In addition to mRNA, interfering RNA offers potential to treat diseases beyond the reach of small molecules. However, therapeutic success hinges on efficient and targeted delivery systems. Lipid nanoparticles (LNPs), especially those produced via microfluidics, have emerged as a leading platform for RNA delivery. delivery. for RNA.
Join Dr. Qiaobin Hu as he explores LNP formulation for siRNA delivery using a microfluidic flow-focusing system.
Optimising lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
866.3 KB
Explore our poster presentation with Qiaobin Hu
Explore additional content
Explore recent blogs:
Croda expands biopharma capabilities through strategic partnership
Croda International Plc (“Croda”), a global leader in specialty ingredients, today announced a strategic supply partnership with Amino GmbH (“Amino”), a leading manufacturer of pharmaceutical-grade...
Meeting the demand for sulphate-free oral care
Formulators are seeking gentle yet effective surfactants that meet regulatory and consumer expectations. That’s where Adinol™ CT95 comes in...
Spotlight on R&D - Tina Baharlou, Industrial Placement Student
This week we caught up with Tina Baharlou, a current Industrial placement student based at our Head Office labs in the UK. Tina has spent the past year immersed in advanced formulation work focused on...